ARTICLE
12 November 2015

CHMP Recommends Extensions For Seven Therapeutic Indications

JD
Jones Day

Contributor

Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
During its October 19–22, 2015 meetings, the Committee for Medicinal Products for Human Use recommended extensions of indication for Cubicin, Edurant, Emend, Volibris, Xalkori, and two extensions of indication for Cosentyx.
European Union Food, Drugs, Healthcare, Life Sciences

During its October 19–22, 2015 meetings, the Committee for Medicinal Products for Human Use ("CHMP") recommended extensions of indication for  Cubicin, Edurant, Emend, Volibris, Xalkori, and two extensions of indication for Cosentyx.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More